A detailed history of Price T Rowe Associates Inc transactions in Avid Bioservices, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 33,326 shares of CDMO stock, worth $409,909. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,326
Previous 33,032 0.89%
Holding current value
$409,909
Previous $236,000 61.02%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.7 - $12.45 $1,969 - $3,660
294 Added 0.89%
33,326 $380,000
Q2 2024

Aug 14, 2024

BUY
$6.34 - $9.28 $17,327 - $25,362
2,733 Added 9.02%
33,032 $236,000
Q1 2024

May 15, 2024

BUY
$5.86 - $8.79 $9,663 - $14,494
1,649 Added 5.76%
30,299 $204,000
Q4 2023

Feb 14, 2024

BUY
$4.64 - $9.56 $11,762 - $24,234
2,535 Added 9.71%
28,650 $187,000
Q3 2023

Nov 14, 2023

BUY
$9.4 - $14.04 $12,849 - $19,192
1,367 Added 5.52%
26,115 $247,000
Q2 2023

Aug 14, 2023

BUY
$12.96 - $20.93 $11,301 - $18,250
872 Added 3.65%
24,748 $346,000
Q1 2023

May 15, 2023

BUY
$13.48 - $18.79 $9,341 - $13,021
693 Added 2.99%
23,876 $448,000
Q4 2022

Feb 14, 2023

BUY
$12.61 - $18.74 $12,723 - $18,908
1,009 Added 4.55%
23,183 $319,000
Q3 2022

Nov 14, 2022

BUY
$15.33 - $20.36 $59,557 - $79,098
3,885 Added 21.24%
22,174 $424,000
Q2 2022

Aug 15, 2022

BUY
$11.63 - $21.55 $4,652 - $8,620
400 Added 2.24%
18,289 $279,000
Q1 2022

May 16, 2022

BUY
$16.63 - $27.73 $23,980 - $39,986
1,442 Added 8.77%
17,889 $364,000
Q4 2021

Feb 14, 2022

BUY
$20.7 - $34.18 $340,452 - $562,158
16,447 New
16,447 $480,000

Others Institutions Holding CDMO

About Avid Bioservices, Inc.


  • Ticker CDMO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,167,500
  • Market Cap $765M
  • Description
  • Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant pro...
More about CDMO
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.